LINC-3
Osilodrostat in Cushing's Disease (LINC-3)
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 137 adults with Cushing's disease, osilodrostat achieved control of mean 24-h urinary free cortisol in a randomised-withdrawal phase versus placebo.
N
137
Disegno
Phase 3 with randomised withdrawal at week 26
Esito
Maintained mUFC control during 8-week withdrawal
Rilevanza
3
Risultato86 % (osilodrostat) vs 29 % (placebo); OR 13.7 (p<0.0001).
Pivonello R, et al. Lancet Diabetes Endocrinol. 2020;8(9):748-761. 10.1016/S2213-8587(20)30240-0
Discussione e critica
Basis of the Isturisa approval for Cushing's disease — oral steroidogenesis inhibitor with predictable cortisol-lowering.